Medical Research Archives





Published: October 31, 2023

Citation: Gopie, F.A. 2023. Total Unilateral Collapsed Lung- A Sequela of Pulmonary Tuberculosis- and Pregnancy Outcome. Medical Research Archives, [online] 11(10). https://doi.org/10.18103/mra. v11i10.4495

Copyright: © 2023 European Society of Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI:

https://doi.org/10.18103/mra. v11i10.4495

ISSN: 2375-1924

CASE REPORT

Total Unilateral Collapsed Lung- A Sequela of Pulmonary Tuberculosis- and Pregnancy Outcome

Fitzgerald A. Gopie^{1,2*}

- 1 Pulmonologist Academic Hospital Paramaribo Suriname, South America
- 2 Senior lecturer Faculty of Medicine, Anton de Kom University of Suriname
- * <u>fitzgeraldgopie@gmail.com</u>

ABSTRACT

Lung tissue damage after pulmonary tuberculosis is common and can result in persistent pulmonary disability with a negative influence on a patient's quality of life. On the other hand, a COVID-19 infection in a previously treated tuberculosis patient with residual pulmonary abnormalities imposes an increased risk of death. On their own, both diseases can have a devastating effect on a patient's pulmonary system and as such be the cause of disability or even death. In this case report of total atelectasis of the left lung due to obliteration of the left main bronchus after tuberculosis treatment, we present a pregnant patient, who despite a significant reduction in pulmonary function, managed to have a pregnancy with a favorable outcome. Thereafter the patient even recovered from a COVID-19 infection, illustrating the resilience of the human body.



Introduction

According to the World Health Organization, an estimated quarter of the global population is infected with tuberculosis (TB). In 2021 about 10.6 million people fell ill with tuberculosis of whom 6.7% were people living with HIV, 450,000 incident patients had multi-drug resistant TB or rifampicin-resistant tuberculosis and about 1.6 million people died of tuberculosis. As such tuberculosis is the second leading cause of infectious death after COVID-19. Moreover, persistent lung tissue damage after pulmonary tuberculosis is common, ranging from pulmonary cavitation to fibrosis and bronchiectasis, airflow obstruction, restrictive ventilatory defects, and impaired diffusion capacity. Other complications could be lobar or multi-lobar atelectasis of the lung caused by caseous material, hemoptysis followed by blood clots, thick inspissated bronchial secretion, granulation tissue, or compression atelectasis due to massive lymphadenopathy.^{1,2,3,4} Persistent pulmonary damage is associated with disability and therefore may significantly limit the patient's quality of life^{5,6,7,8}. On top of that, the recent COVID-19 pandemic learned that patients with pre-existing pulmonary disease have a more severe disease course and higher mortality^{9,10}. As a matter of fact, previous tuberculosis (TB) infection is associated with recovery impairment and an increased risk of death after a COVID-19 infection¹¹. These diseases negatively impacting health status can limit a patient's pulmonary capacity and result in persistent pulmonary disability with diminished pulmonary reserves.

In this case, the report we present a case in which despite the complete destruction of the left lung due to pulmonary tuberculosis, the patient managed to have a pregnancy with a favorable outcome for mother and child, and afterward even vanquished a COVID-19 infection, illustrating the resilience of the lungs.

Case Presentation

A slender 24-year-old, nonsmoking female patient, weighing 48 kg, with no medical history except contact with a pulmonary TB case, presented with a 2-month productive cough but no hemoptysis, fever, and 5 kg weight loss with bilateral pulmonary consolidation on the chest xray.




1. Presenting Chest X-ray in March 2019 with bilateral pulmonary consolidation. The sputum Auramine stain was positive for mycobacteria and the GeneXpert test confirmed Rifampicinsensitive tuberculosis. Her HIV test was negative, and she was diagnosed with drug-sensitive pulmonary tuberculosis. Treatment with first-line tuberculostatic, HREZ (isoniazid, rifampicin, ethambutol, and pyrazinamide) started in March 2019 and continued for 6 months until October 2019. The patient had a good clinical response to treatment, but her chest x-ray showed a peculiar pattern. After initial improvement of the chest x-ray at 3 months of treatment in July 2019, at the end of treatment in October 2019 there was total atelectasis of the left lung, which was confirmed by a CT scan in November 2019.



2. Chest X-ray July 2019, 3 months after treatment, with resolvent of nearly all pulmonary infiltrates.



3. Chest X Ray at the end of treatment in October 2019, with total atelectasis of the left lung.



4. Thoracic CT scan image November 2019, confirming total atelectasis left lung. No significant intrathoracic lymphadenopathy was detected. At bronchoscopy in December 2019 the ostium of the left main bronchus could not be identified, no tumor could be detected, and the ostium of the right main bronchus was patent. Repeat sputum Auramine stain was negative for Mycobacteria. The patient had no pulmonary symptoms, so a wait-and-see policy was performed.

In May 2020 she made an office visit because of dyspnea and being 5 months pregnant. No Chest X-ray was done, but spirometry showed a considerable restriction, with FVC: 1.7 Liter = 50%R, FEV1:1.3 Liter=50%R=75% VC. (FVC: forced vital capacity, FEV1: forced expiratory

volume in 1 second, VC: vital capacity). The primary Ceasar section was advised, and the patient delivered a healthy son in February 2021. In Oct 2021 she made an office visit because of coughing. On the Chest X-ray (CXR # 5), air could be seen in the left upper thoracic field. A diagnosis of upper respiratory tract infection was made, and symptoms were treated.



5. Chest X-ray October 2021, with air in the left upper thoracic region. In January 2022 she acquired COVID-19 infection without significant pulmonary symptoms. Eventually, she missed some office visits, but on her last visit in September 2022, she had no complaints and the Chest X-ray showed persistent air in the left upper thoracic region. A repeat bronchoscopy was not performed.



6: Chest X-ray September 2022, with persistent air in the left upper thoracic region.



Discussion

Tuberculosis infectious is an disease predominantly affecting the lungs. With the current treatment regimens, 85% of people can be cured¹². Although bacteriologically cured, more than 50% of patients suffer from posttuberculosis lung impairment, which is probably host-pathogen immunological based on interaction^{13,14,15}. The resulting lung remodeling is manifested by bronchiectasis, lung tissue scarring, fibrosis, and cavitation⁴. Risk factors for post-tuberculosis lung diseases are multiple episodes tuberculosis, drug-resistant of tuberculosis, delay in diagnosis, and probably smoking¹⁶. Obstructive lung disease, bronchiectasis, tissue scarring, and cavernous lesions are rather common post-tuberculous pulmonary lesions, not atelectasis let alone atelectasis of a whole lung¹⁷. Recently Soriano and Alvarez described a case of near total atelectasis of the left lung due to bronchial occlusion post tuberculosis, in a female patient of 24 years presenting with dyspnea, pleuritic chest pain, and desaturation. The bronchial occlusion was successfully treated with cryotherapy, corticosteroids, and balloon dilatation.18 Previously Watanabe and colleagues have performed surgery for bronchial stricture to prevent obstructive emphysema, bronchiectasis, and progression to total bronchial obliteration¹⁹. The patient in our case was seen for routine follow-up at the end of tuberculosis treatment. To our surprise, her chest X-ray was suggestive of atelectasis of the left lung with total compensatory expansion of the right lung in the upper part of the left thoracic cavity²⁰. Thoracic CT imaging confirmed the chest X-ray findings and showed no structural lesions in the hyperinflated right lung. At bronchoscopy, no lesions were seen in the airways of the right lung, but the ostium of the left main bronchus could not be identified as a consequence of bronchial cicatrization. Although our patient had no risk factors for post-tuberculous lung disease, she developed total atelectasis of the left lung. Spirometry revealed the pulmonary function to be limited to 50% of the expected normal values. As our patient had no complaints, no lesions in the right lung, and the remaining vitality of the left lung, if any, was unclear, we had no reason for invasive bronchial intervention and advocated a wait-and-see policy. As such, the patient was given lifestyle instructions about living on a sole lung. Despite these cautions she eventually became pregnant, had no dyspnea or other adverse events during her pregnancy, and delivered a healthy baby boy via cesarean section. Thereafter, she even repressed a COVID-19 infection in January 2022 and to date has no pulmonary discomfort. In our opinion this case report emphasizes the resilience of the human body/lungs, without the need for surgical intervention in case of atelectasis due to pulmonary tuberculosis, and that a wait-and-see policy can be advocated when no structural lesions are present in the residuary lungs.

Conclusions

In this patient, severe pulmonary damage occurred after a first episode of tuberculosis, in the absence of known risk factors. Expansion of her right lung into the left hemithorax, compensating for total atelectasis of the left lung, allowed for maintaining a reasonable pulmonary function. Despite the still limited function, she managed to resume an almost normal lifestyle, have a favorable pregnancy outcome, and vanquish a COVID-19 infection.

I have no conflict of interest to report, nor have I received funding for the preparation of this case report. I would like to thank S.G.S. Vreden, MD, PhD, infectious disease specialist, for his advice in completing this case report.

References

1. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb). 2011;91(6):497-509. doi:10.1016/j.tube.2011.03.007

2. Long R, Maycher B, Dhar A, Manfreda J, Hershfield E, Anthonisen N. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. Chest 1998;113(4):933-943. doi:10.1378/chest.113.4.933

3. Louis H, Clerf MD. Pulmonary atelectasis in tuberculosis. Chest. 1936;2(12):14-15. doi:10.1378/chest.2.12.14

4. Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis. 2005;192(7):1201-1209. doi:10.1086/444545

5. Abdelaleem NA, Ahmed MK, Mohamed MN, Bayoumi HA. Lung health after tuberculosis: clinical and functional assessment in postpulmonary tuberculosis Egyptian patients. Egypt J Bronchol. 2022; 16(23): e1-e6. doi:10.1186/s43168-022-00123-z

6. Daniels KJ, Irusen E, Pharaoh H, Hanekom S. Post-tuberculosis health-related quality of life, lung function and exercise capacity in a cured pulmonary tuberculosis population in the Breede Valley District, South Africa. S Afr J Physiother. 2019;75(1):1319. Published 2019 Jul 31. doi:10.4102/sajp.v75i1.1319

7. Meghji J, Lesosky M, Joekes E, et al. Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study. Thorax. 2020; 75(3):269-278. doi: 10.1136/thoraxjnl-2019-213808

8. Dias AA, de Oliveira DM, Turato ER, de Figueiredo RM. Life experiences of patients who have completed tuberculosis treatment: a qualitative investigation in southeast Brazil. BMC Public Health. 2013;13:595. Published 2013 Jun 19. doi:10.1186/1471-2458-13-595

9. Martínez-Besteiro E, Molina-Molina M, Gaeta AM, et al. Impact of COVID-19 Infection on Patients with Preexisting Interstitial Lung Disease:

A Spanish Multicentre Study. Arch Bronconeumol. 2023;59(4):273-276. doi:10.1016/j.arbres.2023.01.001

10. Lee H, Choi H, Yang B, et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J. 2021;58(6):2004125. Published 2021 Dec 2. doi:10.1183/13993003.04125-2020

11. Lee H, Choi H, Yang B, et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J. 2021;58(6):2004125. Published 2021 Dec 2. doi:10.1183/13993003.04125-2020

12. Global Tuberculosis Report 2022. World Health Organization; 2022. Accessed September 6,2023.https://www.who.int/publications/i/item/ 9789240061729

13. Pasipanodya JG, Miller TL, Vecino M, et al. Pulmonary impairment after tuberculosis. Chest. 2007;131(6):1817-1824. doi:10.1378/chest.06-2949

14. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev. 2018;27(147):170077. Published 2018 Feb 28. doi:10.1183/16000617.0077-2017

15. Stek C, Allwood B, Walker NF, Wilkinson RJ, Lynen L, Meintjes G. The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy. Front Microbiol. 2018;9:2603. Published 2018 Oct 30. doi:10.3389/fmicb.2018.02603

16. Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge. Respiration. 2021;100(8):751-763. doi:10.1159/000512531

17. Almeida de Souza LE, dos Santos Anjos KL, de Sousa DO et al. Atelectasis as a complication of tuberculosis: a case report. International Archives of Medicine. 2018;11(10).

18. Soriano AM, Álvarez LR. Endobronchial Tuberculosis. Tuberculosis endobronquial. Arch Bronconeumol.2022;58(4):361. doi:10.1016/j.arbres.2021.08.008 19. Watanabe Y, Murakami S, Iwa T. Thorac. cardiovasc. Surgeon 36 (1988) 27 32©Georg Thieme Verlag Stuttgart · New York

20. Madan K, Singh N. Massive compensatory hyperinflation. BMJ Case Rep. 2013; 2013:bcr2013008668. Published 2013 Apr 16. doi:10.1136/bcr-2013-008668